N-乙酰半胱氨酸治疗特发性肺纤维化疗效的系统评价
x

请在关注微信后,向客服人员索取文件

篇名: N-乙酰半胱氨酸治疗特发性肺纤维化疗效的系统评价
TITLE:
摘要: 目的:系统评价N-乙酰半胱氨酸(NAC)治疗特发性肺纤维化(IPF)的疗效,为临床提供循证参考。方法:计算机检索Central数据库、PubMed、EMBase、中国生物医学文献数据库、中国期刊全文数据库、万方数据库和中文科技期刊数据库,收集NAC(不限单药或联用)对比安慰剂/空白对照治疗IPF的随机对照试验(RCT)及半随机对照试验(qRCT),提取资料并采用Cochrane协作网提供的偏倚风险评价工具(2014年版)评价质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入10项研究(2项RCT,8项qRCT),合计742例患者。Meta分析结果显示,与安慰剂/空白对照相比,使用NAC无法降低IPF患者的死亡率[OR=1.14, 95%CI(0.50,2.62),P=0.76],但可以显著提高IPF患者主症状缓解率[OR=3.17, 95%CI(1.98,5.07),P<0.001],改善患者呼吸困难评分[SMD=-2.54, 95%CI(-5.02,-0.06),P=0.04]。结论: NAC治疗IPF不能降低患者的死亡率,但可以缓解患者的主症状,改善呼吸困难。
ABSTRACT: OBJECTIVE: To review therapeutic efficacy of N-acetylcysteine (NAC) for idiopathic pulmonary fibrosis (IPF), and to provide evidence-based reference. METHODS: Retrieved from Central database, PubMed, EMBase, CBM, CJFD, Wanfang database and VIP, randomized controlled trials or semi-randomized controlled trials about NAC (unlimited single drug or combination) vs. placebo/blank control in the treatment of IPF were collected. Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane collaboration’s bias risk assessment tool(2014 edition). RESULTS: A total of 10 studies were included(2 RCT,8 qRCT ), involving 742 patients. Results of Meta-analysis showed that compared to placebo/blank control, NAC couldn’t reduce the mortality of IPF patients [OR=1.14,95%CI(0.50,2.62),P=0.76], but could significantly improve subjective symptom remission rate[OR=3.17,95%CI(1.98,5.07),P<0.001] and  dyspnea score [SMD=-2.54,95%CI(-5.02,-0.06),P=0.04]. CONCLUSIONS: For IPF, NAC can’t decrease the mortality of patients, but can relieve main symptoms and dyspnea.
期刊: 2017年第28卷第27期
作者: 刘丹,张伶俐,蒋学华,全淑燕,胡志强,蒋璐灿,归舸
AUTHORS: LIU Dan,ZHANG Lingli,JIANG Xuehua,QUAN Shuyan,HU Zhiqiang,JIANG Lucan,GUI Ge
关键字: N-乙酰半胱氨酸;特发性肺纤维化;Meta分析;疗效
KEYWORDS: N-acetylcysteine; Idiopathic pulmonary fibrosis; Meta-analysis; Therapeutic efficacy
阅读数: 593 次
本月下载数: 13 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!